La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Fuan Pharmaceutical (Group) Gestione

Gestione criteri di controllo 2/4

We currently do not have sufficient information about the CEO.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	14.9yrs
Durata media del Consiglio di amministrazione	6.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Does Fuan Pharmaceutical (Group) (SZSE:300194) Have A Healthy Balance Sheet?

Jun 07

Fuan Pharmaceutical (Group)'s (SZSE:300194) Shareholders May Want To Dig Deeper Than Statutory Profit

May 02

Insufficient Growth At Fuan Pharmaceutical (Group) Co., Ltd. (SZSE:300194) Hampers Share Price

Apr 03

AMMINISTRATORE DELEGATO

Fuan Pharmaceutical (Group) non ha un CEO, o non abbiamo dati su di loro.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Xue Song Yu	Deputy GM	14.9yrs	CN¥558.90k	0.011% CN¥ 527.9k
Jing Feng	Deputy General Manager	14.9yrs	CN¥561.90k	0.023% CN¥ 1.1m
Rong Chuan Hong	Deputy General Manager	14.9yrs	CN¥496.60k	0.016% CN¥ 772.9k
Yong Ping Sun	Deputy General Manager	4yrs	CN¥565.20k	0.025% CN¥ 1.2m
Tao Huang	Deputy GM & Director	11.7yrs	CN¥670.70k	0.74% CN¥ 36.6m
Xionghui Wu	Deputy General Manager	2.7yrs	CN¥561.50k	0.000080% CN¥ 4.0k
Qin Tang	Secretary of the Board of Directors & Director	14.9yrs	CN¥561.90k	0.024% CN¥ 1.2m

14.9yrs

Durata media

54yo

Età media

Gestione esperta: 300194's management team is seasoned and experienced (14.9 years average tenure).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Xue Song Yu	Deputy GM	14.9yrs	CN¥558.90k	0.011% CN¥ 527.9k
Tao Huang	Deputy GM & Director	11.7yrs	CN¥670.70k	0.74% CN¥ 36.6m
Qin Tang	Secretary of the Board of Directors & Director	14.9yrs	CN¥561.90k	0.024% CN¥ 1.2m
Lu Wang	Vice Chairman	2.7yrs	CN¥687.90k	Nessun dato
Tianxiang Wang	Chairman	14.9yrs	CN¥875.80k	24% CN¥ 1.2b
Zi Wei Guo	Supervisor	6.2yrs	CN¥197.50k	Nessun dato
Wei Wang	Director	6.2yrs	CN¥614.00k	Nessun dato
Wen Shuo Xiong	Independent Director	5.7yrs	CN¥60.00k	Nessun dato
Shu Zhu	Independent Director	5.7yrs	CN¥60.00k	Nessun dato
Geng Chen	Independent Director	2.7yrs	CN¥55.00k	Nessun dato
Yong Yang	Chairman of the Supervisory Board	2.1yrs	Nessun dato	Nessun dato

6.2yrs

Durata media

54yo

Età media

Consiglio di amministrazione esperto: 300194's board of directors are considered experienced (6.2 years average tenure).

Fuan Pharmaceutical (Group) Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Fuan Pharmaceutical (Group) Co., Ltd., Annual General Meeting, May 24, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Fuan Pharmaceutical (Group) Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Does Fuan Pharmaceutical (Group) (SZSE:300194) Have A Healthy Balance Sheet?

Fuan Pharmaceutical (Group) Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 04 June 2024

Fuan Pharmaceutical (Group)'s (SZSE:300194) Shareholders May Want To Dig Deeper Than Statutory Profit

Fuan Pharmaceutical (Group) Co., Ltd. Proposes Final Cash Dividend for 2023

Fuan Pharmaceutical (Group) Co., Ltd., Annual General Meeting, May 24, 2024

First quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.07 in 1Q 2023)

Insufficient Growth At Fuan Pharmaceutical (Group) Co., Ltd. (SZSE:300194) Hampers Share Price

Fuan Pharmaceutical (Group) Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Investor sentiment deteriorates as stock falls 17%

Fuan Pharmaceutical (Group) Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024

Third quarter 2023 earnings released: EPS: CN¥0.07 (vs CN¥0.04 in 3Q 2022)

Investor sentiment improves as stock rises 19%

Second quarter 2023 earnings released: EPS: CN¥0.07 (vs CN¥0.04 in 2Q 2022)

Fuan Pharmaceutical (Group) Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 12 May 2023

First quarter 2023 earnings released: EPS: CN¥0.07 (vs CN¥0.03 in 1Q 2022)

Now 22% undervalued

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.06 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.04 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.04 (vs CN¥0.05 in 2Q 2020)

Fuan Pharmaceutical (Group) Co., Ltd. Announces Implementation of Profit Distribution Plan for A Shares for the Year 2020, Payable on 14 May 2021

First quarter 2021 earnings released: EPS CN¥0.05 (vs CN¥0.06 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.18 (vs CN¥0.25 in FY 2019)

Fuan Pharmaceutical (Group) Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥4.18

New 90-day low: CN¥4.74

Investor sentiment deteriorated over the past week

New 90-day low: CN¥5.42

New 90-day high - CN¥6.57

Fuan Pharmaceutical (Group) Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥6.27

AMMINISTRATORE DELEGATO

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media